Alberto Zanchetti – författare

Left ventricular hypertrophy represents one of the most common complications of the hypertensive state. Indeed, since the Framigham Heart Study, several epidemiological studies have provided clearcut evidence that cardiac hypertrophy represents an important and independent risk factor for the hypertensive patient. Since the introduction of quantitative ultrasound techniques to evaluate cardiac function and state, the research in the field of left ventricular hypertrophy has been par- ticularly active and fruitful, allowing us to gain new information on the pathophysiology of this condition and on its diagnostic and therapeutic approach. The international symposium "Hypertension and the Heart," one of the most impor- tant meetings held on this issue in recent years, promoted by Fondazione Internazionale Menarini, dealt with cardiac hypertrophy in its structural, molecular, pathophysiological, and clinical aspects, and with related complications, such as myocardial ischemia, arrhyth- mias, and congestive heart failure. Prof. A. Zanchetti v CONTENTS Session I: Left Ventricular Hypertrophy: Structural Aspects and Mechanisms 1.Relations of Left Ventricular Geometry and Function to Prognosis in Hypertension ...Richard B. Devereux, Giovanni de Simone, and Mary J. Roman 2. Left Ventricular Hypertrophy, Arterial Compliance, and Aging ...13 Mary 1. Roman, Antonello Ganau, Pier Sergio Saba, and Richard B. Devereux 3. Left Ventricular Hypertrophy and Arterial Blood Pressure in Experimental Models of Hypertension ...23 ...

This book addresses all aspects of white coat hypertension – the phenomenon of raised blood pressure in a medical setting yet not elsewhere – from its history to its pathophysiology, diagnosis and treatment.

This book addresses all aspects of white coat hypertension – the phenomenon of raised blood pressure in a medical setting yet not elsewhere – from its history to its pathophysiology, diagnosis and treatment. White coat hypertension is a common condition, accounting for 30–40% of the overall hypertensive population. While many studies have addressed this condition, controversy still exists over whether it causes an increased risk to sufferers and should be treated.In the volume neurogenic and non-neurogenic mechanisms are discussed and the significance of various predictive factors, evaluated. The association of white coat hypertension with dysmetabolic risk factors, new-onset diabetes and other conditions is carefully reviewed. Further chapters consider the occurrence of asymptomatic organ damage and cardiovascular outcomes in affected patients and helpful guidance is also provided on the controversial issue of when to treat and when not to treat. White Coat Hypertension is based largely on work done during the past 30 years by renowned researchers working in Milan, who have made key contributions in improving knowledge of the condition and whose work is well known across the world.

On the occasion of the symposium on Hypertension in Postmenopausal Women (Monte Carlo, January 19-22, 1994), international scientists and clinicians discussed the various aspects of high blood pressure in older women. This volume presents an overview of this important aspect of both cardiology and gynecology. Special emphasis is given to the different approaches to antihypertension treatment.

On the occasion of the symposium on Hypertension in Postmenopausal Women (Monte Carlo, January 19-22, 1994), international scientists and clinicians discussed the various aspects of high blood pressure in older women. This volume presents an overview of this important aspect of both cardiology and gynecology. Special emphasis is given to the different approaches to antihypertension treatment.